We believe in the power of strong partnerships and collaborations to unlock new opportunities for novel therapeutics that will benefit patients worldwide.

Licensing Partnerships

We have three assets available for out-licensing in heart attack and cancer. We are seeking partnerships to advance these assets further in development. Each peptide therapeutic is focused on a hard-to-drug target for each of the diseases. For all three assets we have statistically significant in vitro and in vivo data.

First in Class Peptide Therapeutics Available for Licensing in Heart Attack and Cancer

Pipeline

  • Note:
  • Interference peptides: block protein-protein interactions
  • Bi-functional Degraders: block the protein signalling pathway and degrade the disease causing protein

We are also seeking partnerships to leverage our platform technologies in protein-protein interference blockade, molecular glues and protein degradation to develop novel peptides against targets identified by partners. Our platforms are versatile and we can rapidly generate lead compounds for diverse diseases.

Current Partnerships

Yaboa Pharmaceutical logo

Yabao – K13

Our current partnership with Yabao Pharmaceutical is to advance the development and commercialization of K13, an interference peptide that we developed for the treatment of stroke. It has the potential to be the first- in-class PTEN- targeting neuroprotective agent for stroke patients. Yabao has rights for China only. We retain freedom to operate in the rest of the world.

Simcere Pharmaceutical logo

Simcere – PP-001

Our partnership with Simcere Pharmaceutical is for the development and commercialization of PP-001 targeting DAPK1 as a potential treatment for stroke. PP-001 is a peptide that we developed using our Chaperone-mediated Autophagy Protein Degradation Technology (CHAPTAC). Simcere has rights for China only. We retain freedom to operate in the rest of the world.

Primedicine logo

Primedicine – PP-002

Our partnership with Primedicine is for the development and commercialization of PP-002, an interference peptide that we developed targeting zD17/JNK as a potential treatment for heart attack. Primedicine has rights for China only. We retain freedom to operate in the rest of the world.